Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Verteporfin photodynamic therapy
Published: 2026-09-17T18:16:06-04:00

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Verteporfin photodynamic therapy

3 evidence topics · 3 sources

Current role of photodynamic therapy in the United States

“Although current practice patterns support anti-VEGF monotherapy for exudative neovascular AMD, verteporfin PDT remains approved for the treatment of subfoveal lesions and can be used in certain situations.” (opens the source at this quote in a new tab)
“However, the EVEREST study demonstrated that fewer anti-VEGF injections were needed in combination therapy compared with anti-VEGF monotherapy in eyes with the PCV variant of neovascular AMD.” (opens the source at this quote in a new tab)
“A severe decrease in central vision occurred within 1 week following treatment in 1% to 4% of patients, which may be permanent” (opens the source at this quote in a new tab)

NICE recommendations on photodynamic therapy

“Do not offer photodynamic therapy alone for late AMD (wet active).” (opens the source at this quote in a new tab)
“Do not offer photodynamic therapy as an adjunct to anti-VEGF as first-line treatment for late AMD (wet active).” (opens the source at this quote in a new tab)

EURETINA recommendation on laser photocoagulation and photodynamic therapy

“While largely superseded by intravitreal pharmaceutical VEGF inhibition, these two older forms of CNV treatment remain a rational therapeutic option for selected patients in whom VEGF inhibition is not advisable.” (opens the source at this quote in a new tab)